Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma

Overview of attention for article published in American Journal of Health-System Pharmacy, February 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

policy: 1 policy source
twitter: 20 X users

patent: 2 patents

Readers on

mendeley: 113 Mendeley

So far, Altmetric has seen 27 X posts from 20 X users, with an upper bound of 98,658 followers.

Pembrolizumab and nivolumab: #PD1 inhibitors for advanced #melanoma https://t.co/WvCdRuEUMH #immunotherapy

#Pembrolizumab y #Nivolumab: Innovaciones terapéuticas significativas en el tratamiento del melanoma avanzado https://t.co/b4VfLElVFo

RT @sefh_: Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma https://t.co/d2cFNzKTYm

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 23 additional X posts.